Zobrazeno 1 - 4
of 4
pro vyhledávání: '"David Pawlyk"'
Autor:
P. Gascon, Hans J. Hansen, Rae Vagg, Karen Burger, Jeffry A. Siegel, Sumathi Murthy, David M. Goldenberg, George Y. Wong, David Pawlyk, Lawrence C. Swayne, Robert M. Sharkey, Daniel O. Izon, Gary M. Levine
Publikováno v:
Cancer. 73:864-877
Background. Colon-specific antigen-p is a tumor-associated antigen present in approximately 60% of colorectal cancers. Preclinical studies have shown that the murine monoclonal antibody Mu-9 has excellent tumor-targeting abilities; therefore, clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff27a38359d6e82a185b7322de5e916d
https://doi.org/10.1002/1097-0142(19940201)73:3+<864::aid-cncr2820731318>3.0.co
https://doi.org/10.1002/1097-0142(19940201)73:3+<864::aid-cncr2820731318>3.0.co
Autor:
Rae Vagg, Hans J. Hansen, Carl M. Pinsky, David M. Goldenberg, Lawrence C. Swayne, Daniel O. Izon, Jeffry A. Siegel, Michael Vezza, Karen Burger, David Pawlyk, George Y. Wong, Sumathi Murthy, Robert M. Sharkey, Helene Pinsky, P. Gascon
Publikováno v:
Cancer. 71:2082-2096
Background. The authors previously reported that an anticarcinoembryonic antigen antibody against a carcinoembryonic antigen (CEA)-specific epitope is preferred for clinical investigations. They developed a second generation, CEA-specific murine mono
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f53285879b84d0d2e181ff1cfe99bfe
https://doi.org/10.1002/1097-0142(19930315)71:6<2082::aid-cncr2820710625>3.0.co
https://doi.org/10.1002/1097-0142(19930315)71:6<2082::aid-cncr2820710625>3.0.co
Autor:
Michele J. Losman, David Pawlyk, Ana M. Natale, Robert M. Sharkey, David M. Goldenberg, Marc Monestier, Otto C. Boerman
Publikováno v:
International journal of cancer. 51(2)
A syngeneic anti-idiotype monoclonal antibody (MAb) (CM-11) directed against an anti-carcinoembryonic antigen (CEA) murine MAb (NP-4) was evaluated as a second antibody (SA) to promote the rapid clearance of radiolabeled NP-4 from the blood. Initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33983b7b1b42c11a604dbf92fb59b7b5
https://pubmed.ncbi.nlm.nih.gov/1568794
https://pubmed.ncbi.nlm.nih.gov/1568794
Autor:
Jo Ann Horowitz, Jeffry A. Siegel, Robert M. Sharkey, Robert E. Lee, David M. Goldenberg, David Pawlyk
Publikováno v:
International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology. 16:553-559
Myelosuppression has been identified as the dose-limiting toxicity in radioimmunotherapy studies. Accurate bone marrow dosimetry is, therefore, necessary to evaluate bone marrow toxicity which may result from systemic cancer treatment with radiolabel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c025b98b6d6ee1b9d1f5f9892f6f998d
https://doi.org/10.1016/0883-2897(89)90070-6
https://doi.org/10.1016/0883-2897(89)90070-6